Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Legal / IP

Kind Pharmaceuticals Resolves Trade Secrets Dispute with Fibrogen Amid HIF-PHI Pipeline Development

Fineline Cube Apr 22, 2024

Kind Pharmaceuticals LLC, a Sino-US pharmaceutical company, along with its Chinese affiliate Hangzhou Andao Pharmaceutical...

Company Drug

Roche’s Alecensa approved by FDA as First ALK Inhibitor for Adjuvant Treatment of NSCLC

Fineline Cube Apr 22, 2024

Roche Holding AG (SWX: ROG; OTCMKTS: RHHBY), a Swiss multinational healthcare company, announced last week...

Company Drug

Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease

Fineline Cube Apr 22, 2024

The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK),...

Company Deals

CareRay Digital Medical Invests $15 Million for Stake in X-Ray Detector Maker ISID

Fineline Cube Apr 22, 2024

CareRay Digital Medical Technology Co., Ltd, a leading medical technology company based in Jiangsu, has...

Drug Medical Device Policy / Regulatory

China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders

Fineline Cube Apr 22, 2024

Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based...

Company Deals

Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs

Fineline Cube Apr 22, 2024

Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD...

Company Deals Hospital

Beijing Sanbo Hospital and AGE Dr. Hospital Management Group Join Forces in Brain Disease Care

Fineline Cube Apr 22, 2024

Beijing Sanbo Hospital Co., Ltd, a prominent healthcare provider in China, has entered into a...

Company Medical Device

Guangzhou LBP Earns NMPA Nod for HER2 Detection Reagent to Guide Breast Cancer Treatment

Fineline Cube Apr 22, 2024

Guangzhou LBP Medicine Science & Technology Co., Ltd (SHA: 688393), a biopharmaceutical company based in...

Company Drug

Sichuan Biokin Gets NMPA Green Light for BL-B01D1 ADC in NSCLC Clinical Trial

Fineline Cube Apr 22, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a leading biopharmaceutical company based in China, has...

Company Drug

Innovent Biologics’ Pemazyre Wins Macau Approval for Cholangiocarcinoma Treatment

Fineline Cube Apr 22, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has received marketing approval...

Company Drug

Kintor Pharmaceutical’s GT20029 Meets Primary Endpoint in Phase II AGA Trial

Fineline Cube Apr 22, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a clinical-stage biotechnology company, has announced that its Phase II...

Company

Jiangsu Hengrui Pharmaceuticals Reports 7.26% Revenue Growth in 2023, Driven by Innovative Drugs

Fineline Cube Apr 19, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has released...

Policy / Regulatory

China’s CDE Issues Guidelines for Pediatric Drug Labeling Updates

Fineline Cube Apr 19, 2024

China’s Center for Drug Evaluation (CDE) has issued a notice outlining the “Detailed Rules for...

Company Drug

GSK’s Shingrix Vaccine Maintains High Efficacy for Over a Decade, Phase III Data Show

Fineline Cube Apr 19, 2024

GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK), the UK-based pharmaceutical giant, has this week released long-term...

Company Drug

AbbVie’s Rinvoq Meets Main Goal in Late-Stage Giant Cell Arteritis Trial

Fineline Cube Apr 19, 2024

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has announced that a late-stage clinical trial...

Company Drug

Chia Tai Tianqing’s Rovadicitinib Meets Main Goal in Myelofibrosis Trial, Eyes Market Filing

Fineline Cube Apr 19, 2024

Chia Tai Tianqing, a renowned pharmaceutical company based in China, has declared that it has...

Company Deals

Shanghai Escugen and Anke Bio Partner to Develop ADC Products with EZWi-Fit Platform

Fineline Cube Apr 18, 2024

Shanghai Escugen, a biopharmaceutical company based in China, has entered into a licensing and cooperation...

Legal / IP

China’s CNIPA and USPTO Pledge to Deepen Intellectual Property Cooperation

Fineline Cube Apr 18, 2024

Shen Changyu, Director of the China National Intellectual Property Administration (CNIPA), met with Kathi Vidal,...

Company Drug

Novartis’s Kesimpta Shows Sustained Efficacy in 6-Year Relapsing MS Study

Fineline Cube Apr 18, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has this week unveiled six-year efficacy data for its...

Company

Abbott Reports Q1 2024 Organic Sales Growth of 4.7%, Led by Pharmaceuticals and Devices

Fineline Cube Apr 18, 2024

Abbott (NYSE: ABT), a global healthcare giant, has this week announced its financial results for...

Posts pagination

1 … 399 400 401 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.